Medicines Co. Stock
€76.00
Your prediction
Financial data and news for Medicines
sharewise wants to provide you with the best news and tools for Medicines, so we directly link to the best financial data sources.
Financials
News
Teva Pharmaceutical Industries’ Anti-IL-15 Antibody Shows Promise in Vitiligo Study
Key Points
- Interested in Teva Pharmaceutical Industries Ltd.? Here are five stocks we like better.
- Teva’s anti-IL-15 antibody showed encouraging 24-week results in a phase 1b vitiligo study
Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease
Key Points
- Interested in Belite Bio, Inc. Sponsored ADR? Here are five stocks we like better.
- Belite Bio says Tinlarebant has completed its Phase 3 DRAGON trial for Stargardt disease, and
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3
Key Points
- Interested in BeOne Medicines Ltd. - Sponsored ADR? Here are five stocks we like better.
- BeOne Medicines used its ASCO investor update to signal a major push beyond hematology
Aquestive Therapeutics Q1 Earnings Call Highlights
Aquestive Therapeutics (NASDAQ:AQST) said it remains on track to resubmit its new drug application for Anaphylm, its epinephrine sublingual film for severe allergic reactions, in the third quarter
Praxis Precision Medicines Q1 Earnings Call Highlights
Praxis Precision Medicines (NASDAQ:PRAX) said it is preparing for two potential U.S. product launches while advancing several late-stage clinical programs, as management outlined first-quarter 2026
A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive Position
John Oyler, the chief executive officer of BeOne Medicines AG (NASDAQ:ONC), sold 109,713 American Depositary Shares in transactions executed on July 20, 2026, and July 21, 2026, according to an SEC
This Stock Has Skyrocketed 125% in 2026 -- and Billionaire Stanley Druckenmiller Is Loading Up on It
Revolution Medicines (NASDAQ: RVMD) aims to replace chemotherapy for some of the most aggressive cancers with its targeted treatments. It directly targets the RAS protein -- which feeds the growth
Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.
Shares of Gilead Sciences (NASDAQ: GILD) have lagged the S&P 500 average this year, rising only 9% despite strong financials and a pipeline that promises to elevate the pharmaceutical company's base
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
Revolution Medicines (NASDAQ: RVMD) spent most of its history as a publicly traded company -- that's since 2020 -- trading for less than $50 a share. The company offers a new approach to oncology
Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd.
Most clinical-stage biotechs are small-cap companies. That makes sense. Not only can it take years -- sometimes over a decade -- to develop novel medicines, but it is also a very risky endeavor
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
The June 10 IPO of Parabilis Medicines (NASDAQ: PBLS) closed up 58% from its $20 offer price. Two days later, Space Exploration Technologies, the largest IPO in history, finished its debut up just
Why Eli Lilly Stock Jumped to a New All-Time High Today
Shares of Eli Lilly (NYSE: LLY) climbed to a record high on Friday, following several promising developments for the medicine maker.
Image source: Getty Images.
The European Medicines Agency's
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
Just a few days after a well-received initial public offering, a director of drug developer Parabilis Medicines (NASDAQ:PBLS) bought shares in the open market.
Director Alan Sebulsky disclosed the
SpaceX Climbed Nearly 20% in Its First Day of Trading. Here's Where the Stock Price Will Be in 3 Months, According to History.
SpaceX (NASDAQ: SPCX) advanced more than 19% on Friday, its first day of trading -- and reached a market value of $2.1 trillion. This immediately puts it in the league of the world's biggest tech
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?
This year is turning out to be a massive one for initial public offerings, with Cerebras Systems delivering the biggest so far and SpaceX on track to launch the largest ever. On top of that
Can Revolution Medicines Be a Game-Changer Stock?
A diagnosis of pancreatic cancer is one of the most feared things in medicine. The disease has the highest mortality rate of all cancers. In 2026, roughly 67,530 Americans will be diagnosed with the
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock.
Revolution Medicines (NASDAQ: RVMD) looks unstoppable. The clinical-stage biotech company has been riding the wave of impressive clinical progress, sending its stock price up nearly 100% this year
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial
Erasca (NASDAQ:ERAS), a developer of therapies for RAS/MAPK pathway-driven cancers, closed at $9.90, down 48% on Tuesday. Shares fell after the company disclosed a patient death from pneumonitis in
Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It Seems
If a stock has a market cap of nearly $30 billion, you would probably expect its business to be well developed, generating significant revenue, and likely profitable. But there's one stock trading
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.
According to a Securities and Exchange Commission (SEC) filing dated Feb. 17, 2026, Nextech Invest, Ltd. bought 855,097 additional shares of Relay Therapeutics (NASDAQ:RLAY). The estimated
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
On February 17, 2026, 5AM Venture Management reported selling its entire stake in Praxis Precision Medicines (NASDAQ:PRAX), an estimated $9.01 million trade based on last-disclosed position values.
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter
Cormorant Asset Management disclosed a sale of 50,000 shares of Praxis Precision Medicines (NASDAQ:PRAX) in a February 17, 2026, SEC filing, with an estimated transaction value of $9.31 million
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline
On February 17, 2026, Deerfield Management Company disclosed a buy of Praxis Precision Medicines (NASDAQ:PRAX), adding 62,500 shares in a trade estimated at $11.64 million based on quarterly average
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings
On February 17, 2026, Driehaus Capital Management disclosed a buy of 432,510 shares of Praxis Precision Medicines (NASDAQ:PRAX), an estimated $80.54 million trade based on quarterly average pricing.
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year
On February 17, 2026, Baker Bros. Advisors LP disclosed a buy of 437,000 Praxis Precision Medicines (NASDAQ:PRAX) shares, estimated at $81.38 million based on quarterly average pricing.
According to